Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

In a multivariate regression analysis, utilizing baseline CA19-9, and baseline ctDNA KRAS as continuous variables, along with the co-variates of interest, stage, gender (sex), and baseline European Cooperative Oncology Group (ECOG) performance score, ctDNA KRAS remained highly significant for TTP (HR = 1.45; 95% CI 1.15–1.83, p = 0.0017), while baseline CA19-9 was less significant (HR = 1.27; 95% CI 1.03–1.58, p = 0.0284) along with sex (HR = 0.79; 95% CI 0.63–0.99, p = 0.0400) (Table 3 ).

also in 132,142 other papers

In contrast, those with a diagnosis of stage IV disease had a borderline significant association based on their ctDNA KRAS level ( p = 0.0554; Figure 5B ).

also in 11,409 other papers